Don’t miss out - Get your tickets early!

Join this FREE, 60-minute online webinar to gain access to insights and learn about ground breaking treatments to chronic mental health conditions.

Interview with Professor Rachel Yehuda PhD (USA)
Professor of Psychiatry and Neuroscience, Director of the Traumatic Stress Studies Division at the Mount Sinai School of Medicine

PTSD is a disorder that is becoming more prevalent in our society and is very difficult to treat. Most of the currently used psychotherapies for the treatment of PTSD are exposure-based therapies, which rely on imaginal visualization of the traumatic events and exposure to trauma-related cues that trigger fear responses. The role of the therapists is to instruct the patient to relive the trauma and to provide a cognitive framework for change. For some patients this is difficult, leading to non-response or treatment dropout. Engagement in psychotrauma focused therapy may be difficult for some patients, especially in cases of extreme affect dysregulation, shame or guilt associated with the recall of traumatic memories.

There is an urgent need for new treatments for PTSD for this group of patients. The use of psychedelic-assisted therapies, in particular MDMA-assisted therapy is offering opportunities to support critical aspects of the psychotherapeutic process. In this webinar elements of PTSD, its neuroscience, history and exploration of the landscape towards MDMA and other psychedelics will be discussed.

WEBINAR SESSION

Topic: Psychedelic-Assisted Psychotherapy and Post-Traumatic Stress Disorder

Date: Wednesday 4 November 2020

Time: 11:55am for 12:00pm start – 1:15pm (incl Q&A) (AEDT)

The presentation WILL BEGIN AT 12:00pm.

Location: Online. A link will be emailed to you with the viewing details.

Don’t miss out - Get your tickets early!

More about medicinal psychedelic treatments:

Psychedelic-assisted treatments offer enormous potential in providing a meaningful alternative to current treatments for mental illness. PTSD is a debilitating condition that affects tens of millions of people worldwide, with many more trauma victims diagnosed with comorbid conditions such as depression, anxiety and eating disorders. In recent clinical trials, MDMA has been shown to produce reliable clinical improvements, restoring patient safety and self-agency even for individuals who have suffered with PTSD for many years, and for whom many treatments have failed.

The wave of clinical psychedelic research and regulatory support is rapidly building, with experts forecasting the availability of psychedelic-assisted treatments in the US and EU within the next 2 to 5 years, subject to positive clinical outcomes in large trials that are currently underway.

More about the presenters

Dr Rachel Yehuda (USA)
PH.D.
Professor of Psychiatry and Neuroscience at the Icahn School of Medicine at Mount Sinai

Dr Rachel Yehuda, Ph.D. is the Director of the Center for the Study of Psychedelic Psychotherapy and Trauma, Vice Chair for Veterans Affairs for the Psychiatry Department and a Professor of Psychiatry and Neuroscience at the Icahn School of Medicine at Mount Sinai as well as the Director of Mental Health at the Bronx Veterans Affairs Medical Center and the Director of the Traumatic Stress Studies Division.

Throughout her career her research has focused on the study of the enduring effects of trauma exposure, particularly PTSD, as well as associations between biological and psychological measures. She has investigated novel treatment approaches for PTSD and the biological factors that may contribute to differing treatment outcomes for the purpose of developing personalized medicine strategies for treatment matching in PTSD.

This work has resulted in an approved US patent for a PTSD blood test. Recently, Dr Yehuda’s laboratory has used advances in stem cell technology to examine PTSD gene expression networks in induced neurons. The Center for Psychedelic Psychotherapy and Trauma integrates sophisticated brain imaging and molecular neuroscience in PTSD with clinical trials using MDMA assisted psychotherapy and other related medicines. She has authored more than 450 published papers, chapters, and books in the field of trauma and resilience, focusing on topics such as PTSD prevention and treatment, molecular biomarkers of stress vulnerability and resilience, and intergenerational effects of trauma and PTSD.

Tania de Jong AM
LL.B (Hons), GradDipMus
Founder & Deputy Chair of Mind Medicine Australia

Tania de Jong AM is a trail-blazing Australian soprano, award-winning social entrepreneur, creative innovation catalyst, spiritual journey woman, storyteller and global speaker. Tania is one of Australia’s most successful female entrepreneurs and innovators developing 5 businesses and 3 charities over the past 3 decades. She is Founder and Executive Producer of future-shaping events series, Creative Innovation Global. She was appointed a Member of the Order of Australia in June 2008 and named one of the 100 Women of Influence and the 100 Australian Most Influential Entrepreneurs in 2018.

Support psychedelic research and therapy development

By donating to Mind Medicine Australia, you will be helping us to accelerate the availability and best practice of psychedelic-assisted psychotherapy in Australia. We are a small organisation doing big things – we need your support.

Please click here to make a tax-deductible donation.

Disclaimer

Mind Medicine Australia does not encourage or facilitate illegal use of psychedelics or plant medicines. MMA focus is focused on clinical and legal use only supported by the emerging science and legislative processes. Mind Medicine Australia reserves the right to record and publish webinars on various social media platforms. You agree that you will not discuss any names, locations or specific details of illegal use of psychedelics both verbally or via any written forms of communication via Mind Medicine Australia social media platforms (for example facebook, instagram and zoom private and public chat forms during the webinar). Breaches of these guidelines may result in not being able to participate in the event. We thank you for support and cooperation on these matters.